Creon

(Pancrelipase)

Creon

Drug updated on 10/23/2023

Dosage FormCapsule (oral; lipase/protease/amylase: 3,000 USP/9,500 USP/15,000 USP), Capsule (oral; lipase/protease/amylase: 6000 USP, 19,000 USP, 30,000 USP), Capsule (oral; lipase/protease/amylase: 120,000 USP, 38,000 USP, 60, 000 USP), Capsule (oral: 24,000 USP, 76,000 USP, 120,000 USP) Capsule (oral: 36,000 USP, 114,000 USP, 180,000 USP)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Product Monograph / Prescribing Information

Document TitleYearSource
Creon (pancrelipase) Prescribing Information.2022AbbVie Inc. North Chicago, IL

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Evidence-based clinical practice guidelines for chronic pancreatitis 2021.2022Journal of Gastroenterology